Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma

IMPORTANCE: Carfilzomib-lenalidomide-dexamethasone therapy yields deep responses in patients with newly diagnosed multiple myeloma (NDMM). It is important to gain an understanding of this combination’s tolerability and impact on minimal residual disease (MRD) negativity because this end point has be...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:JAMA Oncol
Autores principales: Korde, Neha, Roschewski, Mark, Zingone, Adriana, Kwok, Mary, Manasanch, Elisabet E., Bhutani, Manisha, Tageja, Nishant, Kazandjian, Dickran, Mailankody, Sham, Wu, Peter, Morrison, Candis, Costello, Rene, Zhang, Yong, Burton, Debra, Mulquin, Marcia, Zuchlinski, Diamond, Lamping, Liz, Carpenter, Ashley, Wall, Yvonne, Carter, George, Cunningham, Schuyler C., Gounden, Verena, Sissung, Tristan M., Peer, Cody, Maric, Irina, Calvo, Katherine R., Braylan, Raul, Yuan, Constance, Stetler-Stevenson, Maryalice, Arthur, Diane C., Kong, Katherine A., Weng, Li, Faham, Malek, Lindenberg, Liza, Kurdziel, Karen, Choyke, Peter, Steinberg, Seth M., Figg, William, Landgren, Ola
Formato: Artigo
Lenguaje:Inglês
Publicado: 2015
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6662597/
https://ncbi.nlm.nih.gov/pubmed/26181891
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2015.2010
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares